Τρίτη 3 Οκτωβρίου 2017

CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy

Publication date: Available online 19 September 2017
Source:European Journal of Surgical Oncology (EJSO)
Author(s): Mathew A. Kozman, Oliver M. Fisher, Bree-Anne J. Rebolledo, Sarah J. Valle, Nayef Alzahrani, Winston Liauw, David L. Morris
BackgroundSerum tumour levels have been shown to be prognostic in patients with epithelial appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei (PMP)). A singular index which incorporates both tumour activity (as depicted by serum tumour marker levels) and tumour volume (as depicted by peritoneal carcinomatosis index (PCI)), may give a more precise surrogate of tumour biological behaviour. The prognostic implication of this index has not yet been reported.MethodsA retrospective cohort study of all patients with PMP managed from 1996 to 2016 with cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) was performed by analysing the survival effect of the ratio of preoperative serum CEA, CA19.9 and CA125 to PCI.ResultsThree hundred and eighty-six patients were included. In patients with low-grade PMP, elevated CA19-9/PCI ratio resulted in poorer median overall survival times (104 months vs NR, 95%CI 83 – NR, log-rank p<0.001) and was an independent predictor of reduced overall survival on multivariable analysis (adjusted HR 5.60, 95%CI 1.60 - 19.68, p = 0.007). In patients with high-grade PMP, no statistically significant difference in survival was recognised. Recurrence free survival times were not significantly affected by serum tumour marker levels or ratios.ConclusionCA19-9/PCI ratio is an independent prognostic factor for overall survival in patients with low-grade PMP undergoing CRS and IPC. By accounting for both tumour activity and tumour volume simultaneously, this novel index behaves as a surrogate of tumour biology and provides a useful adjunct for decisions regarding treatment allocation in this patient group.



http://ift.tt/2xRjiy7

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου